EUVIMEDEUVIMED entdecken
Crossref

MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway

Xia Yuan, Kun Zhang, Dan Wang, Jie Li, Peng Lyu, Xuemei Zhao, Kang Zhang, Hongting Li, Bo Liu, Liping Ma iD

Liver International · 2025

DOI: 10.1111/liv.70302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Xia Yuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Target Discovery and Protein Drug Development in Major Diseases, School of Bioscience and Technology, Chengdu Medical College, Chen…. Hauptthemen laut MEDLINE: MicroRNAs, Insulin Receptor Substrate Proteins, Hepatic Stellate Cells, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the research project of Sichuan provincial medical association, Chengdu Medical College Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Hepatic fibrosis is a progressive response to chronic liver injury. A key event in the development of hepatic fibrosis is the activation of hepatic stellate cells (HSCs); emerging research indicates that microRNAs play crucial roles in regulating HSCs activation. However, the specific roles of miR‐126‐3p (miR‐126) and miR‐195‐5p (miR‐195) in liver fibrosis remain inadequately understood.

Methods

We examined the expression of miR‐126 and miR‐195 in activated HSCs, fibrotic liver tissues from animal models, and blood samples from patients with liver disease. The effects on cell proliferation and migration were investigated by MTT, colony formation assay, cell wound healing assay, and Transwell assay. Finally, we evaluated the effect of miR‐126 and miR‐195 on the progression of liver fibrosis in mice.

Results

We revealed that miR‐126 and miR‐195 were markedly downregulated in activated HSCs, fibrotic liver tissues from animal models, and blood samples from patients with liver diseases. Functional experiments demonstrated that the overexpression of miR‐126 and miR‐195 significantly inhibited the proliferation, migration, and fibrotic markers expression in HSCs. Conversely, silencing miR‐126 and miR‐195 produced the opposite effects. Further mechanistic studies showed that miR‐126 and miR‐195 downregulate insulin receptor substrate 1 (IRS1) or phosphoinositide 3‐kinase regulatory subunit 2 (PIK3‐R2), respectively, thereby inhibiting the pro‐fibrotic signalling pathway (IRS1/PI3K) and regulating the functions of HSCs. Importantly, in vivo experiments demonstrated that miR‐126 and miR‐195 markedly alleviated CCL 4 ‐induced hepatic fibrosis in mice.

Conclusions

Our results unravel that miR‐126 and miR‐195 inhibit liver fibrosis by suppressing the IRS/PI3K pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsInsulin Receptor Substrate ProteinsHepatic Stellate CellsLiver CirrhosisAnimalsSignal TransductionHumansMiceCell ProliferationPhosphatidylinositol 3-KinasesMaleCell MovementMice, Inbred C57BLDown-RegulationLiverCarbon Tetrachloride

Stichwörter der Autor:innen

HSCsIRS1/PI3K signalling pathwayliver fibrosismiRNAs

Substanzen

MicroRNAsInsulin Receptor Substrate ProteinsMIRN195 microRNA, humanPhosphatidylinositol 3-KinasesMIRN126 microRNA, humanIRS1 protein, humanMIRN195a microRNA, mouseMIRN126 microRNA, mouseIrs1 protein, mouseCarbon Tetrachloride

Autor:innen und Institutionen

  • Key Laboratory of Target Discovery and Protein Drug Development in Major Diseases, School of Bioscience and Technology, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China.
  • The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Nanbu People's Hospital, Chengdu, People's Republic of China.
  • The 3rd Affiliated Hospital of Chengdu Medical College, Pidu District People's Hospital of Chengdu, Chengdu, Sichuan, People's Republic of China.

ORCID-Profile: Liping Ma

Förderung

  • National Natural Science Foundation of China
  • the research project of Sichuan provincial medical association
  • Chengdu Medical College Program
  • Technological Innovation R&D Project of Chengdu Science and Technology Bureau

Zitieren

APA

Yuan, X., Zhang, K., Wang, D., Li, J., Lyu, P., Zhao, X., Zhang, K., Li, H., Liu, B., & Ma, L. (2025). MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway. Liver International. https://doi.org/10.1111/liv.70302

Vancouver

Yuan X, Zhang K, Wang D, Li J, Lyu P, Zhao X, et al. MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway. Liver International. 2025. doi:10.1111/liv.70302

BibTeX
@article{Yuan2025,
  author = {Yuan, Xia and Zhang, Kun and Wang, Dan and Li, Jie and Lyu, Peng and Zhao, Xuemei and Zhang, Kang and Li, Hongting and Liu, Bo and Ma, Liping},
  title = {MiR ‐126‐3p and MiR ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1 / PI3K Signalling Pathway},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70302}
}
Kostenlos starten →